Skip to main content
Top
Published in: Allergy, Asthma & Clinical Immunology 1/2016

Open Access 01-12-2016 | Research

Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey

Authors: Pascal Demoly, Anne Broué-Chabbert, François Wessel, Antoine Chartier

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2016

Login to get access

Abstract

Background

Allergen immunotherapy (AIT) may be prescribed for patients with allergic rhinitis (AR) induced by house dust mites (HDM) whether asthma is present or not. Current guidelines provide insufficient support for therapeutic management strategy of these patients. Allergists however have long-term experience with AIT. This study aims to describe the characteristics of the patients seen in clinical practice with HDM allergy and the process used to determine whether AIT should be initiated.

Methods

This was an observational, multicenter, prospective and cross-sectional study, conducted in France from 2013 to 2014 with a representative sample of allergy specialists. Any patient over 5 years of age with confirmed HDM allergy untreated with AIT within the last 12 months was eligible. Data were prospectively collected using physician and patient questionnaires.

Results

A total of 1589 patients (60 % adults, 40 % children) were included by 195 randomly selected allergists. A subgroup of 1212 patients (median age: 22 years; 52 % women) were selected for AIT treatment with a median time of AR diagnosis of 3 years. Amongst these, 59 % had a moderate to severe persistent AR according to AR and its Impact on Asthma guidelines, 57.5 % were polysensitized, and 56.5 % also suffered from conjunctivitis (median rhinitis total symptom score: 11). Asthma was present in 42 % of patients, and was controlled according to Global Initiative for Asthma guidelines in 62 % of patients. The asthma control questionnaire score was 1–1.5 in 20 % and ≥1.5 in 37 % of patients. A total of 57 % patients received a prescription of ≥2 medications (mainly antihistamines). Usual daily activities and sleep quality were slightly-to-moderately impaired as the mean rhinoconjunctivitis quality of life questionnaire score was 2.7 ± 1.5. The major driver of AIT prescription is AR uncontrolled by previous medications leading to patient dissatisfaction.

Conclusions

HDM-AR associated conjunctivitis was present in 60 % and asthma in 40 % of cases. In >40 % of these cases, asthma was inadequately controlled at the start of AIT.
Literature
1.
go back to reference Global Allergy and Asthma European Network, Grading of Recommendations Assessment, Development and Evaluation Working Group, Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;2010(126):466–76. Global Allergy and Asthma European Network, Grading of Recommendations Assessment, Development and Evaluation Working Group, Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;2010(126):466–76.
3.
go back to reference Calderón MA, Linneberg A, Kleine-Tebbe J, De Blay F, Fernandez Hernandez, de Rojas D, Virchow JC, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136(1):38–48.CrossRefPubMed Calderón MA, Linneberg A, Kleine-Tebbe J, De Blay F, Fernandez Hernandez, de Rojas D, Virchow JC, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136(1):38–48.CrossRefPubMed
4.
go back to reference Ridolo E, Caffarelli C, Olivieri E, Montagni M, Incorvaia C, Baiardini I, et al. Quality of sleep in allergic children and their parents. Allergol Immunopathol (Madr). 2015;43(2):180–4.CrossRefPubMed Ridolo E, Caffarelli C, Olivieri E, Montagni M, Incorvaia C, Baiardini I, et al. Quality of sleep in allergic children and their parents. Allergol Immunopathol (Madr). 2015;43(2):180–4.CrossRefPubMed
5.
go back to reference Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106(2 Suppl):S12–6.CrossRefPubMed Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106(2 Suppl):S12–6.CrossRefPubMed
6.
go back to reference Zuberbier T, Lötvall J, Simoens S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69(10):1275–9.CrossRefPubMed Zuberbier T, Lötvall J, Simoens S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69(10):1275–9.CrossRefPubMed
8.
go back to reference Frati F, Scurati S, Dell’Albani I, Puccinelli P, Incorvaia C, Passalacqua G. Evaluation of house dust mite allergy in real life: patients’ characteristics and satisfaction with treatment. Eur Ann Allergy Clin Immunol. 2014;46(1):17–21.PubMed Frati F, Scurati S, Dell’Albani I, Puccinelli P, Incorvaia C, Passalacqua G. Evaluation of house dust mite allergy in real life: patients’ characteristics and satisfaction with treatment. Eur Ann Allergy Clin Immunol. 2014;46(1):17–21.PubMed
9.
go back to reference Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis. 2012;6(1):11–23.CrossRefPubMed Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis. 2012;6(1):11–23.CrossRefPubMed
10.
go back to reference Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13(11):1543–56.CrossRefPubMed Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13(11):1543–56.CrossRefPubMed
11.
go back to reference Bozek A, Ignasiak B, Filipowska B, Jarzab J. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy. 2013;43(2):242–8.CrossRefPubMed Bozek A, Ignasiak B, Filipowska B, Jarzab J. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy. 2013;43(2):242–8.CrossRefPubMed
12.
go back to reference Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66(6):740–52.CrossRefPubMed Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66(6):740–52.CrossRefPubMed
13.
go back to reference Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.CrossRefPubMedPubMedCentral Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.CrossRefPubMedPubMedCentral
15.
go back to reference Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130(5):1049–62.CrossRefPubMed Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130(5):1049–62.CrossRefPubMed
16.
go back to reference Van Hoecke H, Van Cauwenberge P, Thas O, Watelet JB. The ARIA guidelines in specialist practice: a nationwide survey. Rhinology. 2010;48(1):28–34.PubMed Van Hoecke H, Van Cauwenberge P, Thas O, Watelet JB. The ARIA guidelines in specialist practice: a nationwide survey. Rhinology. 2010;48(1):28–34.PubMed
17.
go back to reference Demoly P, Calderon MA, Casale T, Scadding G, Annesi-Maesano I, Braun J-J. Assessment of disease-control in allergic rhinitis. Clin Transl Allergy. 2013;3(1):7.CrossRefPubMedPubMedCentral Demoly P, Calderon MA, Casale T, Scadding G, Annesi-Maesano I, Braun J-J. Assessment of disease-control in allergic rhinitis. Clin Transl Allergy. 2013;3(1):7.CrossRefPubMedPubMedCentral
18.
go back to reference Papadopoulos NG, Bernstein JA, Demoly P, Dykewicz M, Fokkens W, Hellings PW, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474–94.CrossRefPubMed Papadopoulos NG, Bernstein JA, Demoly P, Dykewicz M, Fokkens W, Hellings PW, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474–94.CrossRefPubMed
19.
go back to reference Didier A, Chartier A, Démonet G. Specific sublingual immunotherapy: for which profiles of patients in practice? Midterm analysis of ODISSEE (observatory of the indication and management of respiratory allergies. [rhinitis and/or conjunctivitis and/or allergic asthma] by specific sublingual immunotherapy). Rev Fr Allergol. 2010;50(5):426–33.CrossRef Didier A, Chartier A, Démonet G. Specific sublingual immunotherapy: for which profiles of patients in practice? Midterm analysis of ODISSEE (observatory of the indication and management of respiratory allergies. [rhinitis and/or conjunctivitis and/or allergic asthma] by specific sublingual immunotherapy). Rev Fr Allergol. 2010;50(5):426–33.CrossRef
20.
go back to reference Demoly P, Jankowski R, Chassany O, Bessah Y, Allaert FA. Validation of a self-questionnaire for assessing the control of allergic rhinitis. Clin Exp Allergy. 2011;41(6):860–8.CrossRefPubMed Demoly P, Jankowski R, Chassany O, Bessah Y, Allaert FA. Validation of a self-questionnaire for assessing the control of allergic rhinitis. Clin Exp Allergy. 2011;41(6):860–8.CrossRefPubMed
21.
go back to reference Franzke N, Schafer I, Jost K, Blome C, Rustenbach SJ, Reich K, et al. A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy. 2011;66(5):665–70.CrossRefPubMed Franzke N, Schafer I, Jost K, Blome C, Rustenbach SJ, Reich K, et al. A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy. 2011;66(5):665–70.CrossRefPubMed
22.
go back to reference Scott AJ, Knott M. A cluster analysis method for grouping means in the analysis of variance. Biometrics. 1974;30:507–12.CrossRef Scott AJ, Knott M. A cluster analysis method for grouping means in the analysis of variance. Biometrics. 1974;30:507–12.CrossRef
23.
go back to reference Brazilian ISAAC Group, Solé D, Camelo-Nunes IC, Wandalsen GF, Rosário NA, Sarinho EC. Is allergic rhinitis a trivial disease? Clinics. 2011;66(9):1573–7.CrossRef Brazilian ISAAC Group, Solé D, Camelo-Nunes IC, Wandalsen GF, Rosário NA, Sarinho EC. Is allergic rhinitis a trivial disease? Clinics. 2011;66(9):1573–7.CrossRef
24.
go back to reference Trebuchon F, Lhéritier-Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy. 2014;4:15.CrossRefPubMedPubMedCentral Trebuchon F, Lhéritier-Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy. 2014;4:15.CrossRefPubMedPubMedCentral
25.
go back to reference Biagtan M, Viswanathan R, Bush RK. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps? Curr Allergy Asthma Rep. 2014;14(12):482.CrossRefPubMed Biagtan M, Viswanathan R, Bush RK. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps? Curr Allergy Asthma Rep. 2014;14(12):482.CrossRefPubMed
26.
go back to reference Didier A, Campo P, Moreno F, Durand-Perdriel F, Marin A, Chartier A. Dose-dependent immunological responses after a 6-month course of sublingual house dust mite immunotherapy in patients with allergic rhinitis. Int Arch Allergy Immunol. doi: 10.1159/000442467. Didier A, Campo P, Moreno F, Durand-Perdriel F, Marin A, Chartier A. Dose-dependent immunological responses after a 6-month course of sublingual house dust mite immunotherapy in patients with allergic rhinitis. Int Arch Allergy Immunol. doi: 10.​1159/​000442467.
27.
go back to reference Bender BG, Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. J Allergy Clin Immunol Pract. 2014;2(2):152–5.CrossRefPubMed Bender BG, Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. J Allergy Clin Immunol Pract. 2014;2(2):152–5.CrossRefPubMed
28.
go back to reference Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132(2):353–60.CrossRefPubMed Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132(2):353–60.CrossRefPubMed
29.
go back to reference Silva D, Pereira A, Santos N, Plácido JL. Costs of treatment affect compliance to specific subcutaneous immunotherapy. Eur Ann Allergy Clin Immunol. 2014;46(2):87–94.PubMed Silva D, Pereira A, Santos N, Plácido JL. Costs of treatment affect compliance to specific subcutaneous immunotherapy. Eur Ann Allergy Clin Immunol. 2014;46(2):87–94.PubMed
30.
go back to reference Savi E, Peveri S, Senna G, Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy. 2013;68(9):1193–5.PubMed Savi E, Peveri S, Senna G, Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy. 2013;68(9):1193–5.PubMed
31.
go back to reference Ozdemir C, Yazi D, Gocmen I, Yesil O, Aydogan M, Semic-Jusufagic A, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol. 2007;18(6):508–15.CrossRefPubMed Ozdemir C, Yazi D, Gocmen I, Yesil O, Aydogan M, Semic-Jusufagic A, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol. 2007;18(6):508–15.CrossRefPubMed
32.
go back to reference Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009;64(11):1570–9.CrossRefPubMed Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009;64(11):1570–9.CrossRefPubMed
33.
go back to reference Larenas-Linnemann D, Blaiss M, Van Bever HP, Compalati E, Baena-Cagnani CE. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009–2012. Ann Allergy Asthma Immunol. 2013;110(6):402–15.CrossRefPubMed Larenas-Linnemann D, Blaiss M, Van Bever HP, Compalati E, Baena-Cagnani CE. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009–2012. Ann Allergy Asthma Immunol. 2013;110(6):402–15.CrossRefPubMed
34.
go back to reference Ciprandi G, Marseglia GL. Safety of sublingual immunotherapy. J Biol Regul Homeost Agents. 2011;25(1):1–6.PubMed Ciprandi G, Marseglia GL. Safety of sublingual immunotherapy. J Biol Regul Homeost Agents. 2011;25(1):1–6.PubMed
Metadata
Title
Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey
Authors
Pascal Demoly
Anne Broué-Chabbert
François Wessel
Antoine Chartier
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Allergy, Asthma & Clinical Immunology / Issue 1/2016
Electronic ISSN: 1710-1492
DOI
https://doi.org/10.1186/s13223-016-0119-z

Other articles of this Issue 1/2016

Allergy, Asthma & Clinical Immunology 1/2016 Go to the issue